🔗 Share this article

As the United States proceeds with sweeping changes to its immunization schedules, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by questioning coronavirus vaccines in the pandemic and has focused upon possible deaths following COVID-19 vaccination in her brief time at the FDA.

Planned Changes to Pediatric Vaccine Program

Public health authorities were set to unveil major changes to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s vaccine program, sources say – a major change that would put the US at odds with much of the international standard with insufficient data for benefit. The announcement has been postponed until the new year.

Rather than the top vaccines chief, Dr. Høeg is set to address the audience at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

A Shift at the Agency

This interim role could signify a tighter collaboration between the drug and vaccine branches as Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Høeg has repeatedly called for halting certain childhood immunization guidelines in the US in order to be more in line with Denmark, a society with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than medication approval.

Questions Over Qualifications

The appointee has little discernible background in pharmaceutical research, oversight or administrative roles, which has been standard for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in managing a sizeable institution. She lacks background in pharmaceutical oversight.”

Former commissioners of the center would “be deeply familiar with legal statutes and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that prior appointees who ran the center have had.”

CDER has an enormous workload at the FDA, Woodcock stated.

“Everybody just focuses on the new drug program, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and other areas, and every single one must be managed,” she noted. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial leadership component to the position, which manages more than 5,000 employees. “It is a massive management job, if you perform it correctly,” the former official added.

Official Statement and Contentious Initiatives

In response to inquiries about Dr. Høeg's credentials and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a representative stated that the “concerns rely on inaccurate presumptions”.

“Her experience matches the functions of her job,” the spokesperson said, pointing to the period Høeg spent advising the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed rapid therapy clearance system that reportedly troubled her preceding directors. “How are these therapies being picked for this fast-track system? Who makes the decisions?” Howard questioned. “There’s a lot of secrecy going on at the agency right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards laxer rules of all drugs, except for vaccines.”

Documented History on Vaccines

With vaccines, Dr. Høeg has a clearer, if concerning, history, some experts have noted. She authored a analysis using unverified volunteer-provided data to estimate the incidence of myocarditis after Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are riskier than they are.

Part of her “wish list” for the current federal leadership included changing regulations for novel immunizations and halting “optional” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has allegedly suggested barring adolescent males from obtaining COVID-19 vaccinations.

“She is an all-around true believer who commences with her conclusions and reverse-engineers to accommodate the evidence in a highly deceptive, dishonest fashion,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow dissenters, {like|